What is LifeBio?
LifeBio operates at the forefront of the agetech sector, utilizing a sophisticated AI-powered platform to facilitate reminiscence therapy and structured storytelling. By enabling individuals to document their life histories, the company addresses the psychological impacts of isolation, depression, and cognitive impairment. Its market position is defined by a unique synthesis of digital health innovation and compassionate care, positioning it as a vital resource for healthcare providers, caregivers, and families seeking to foster intergenerational connections and improve mental well-being among the elderly.
How much funding has LifeBio raised?
LifeBio has raised a total of $3M across 2 funding rounds:
Debt
$135K
Grant
$2.9M
Debt (2021): $135K with participation from PPP
Grant (2025): $2.9M led by National Institute on Aging
Key Investors in LifeBio
National Institute on Aging
A federal research institute under the NIH dedicated to advancing scientific knowledge on aging, Alzheimer's disease, and related dementias through rigorous research and grant support.
PPP
Public-Private Partnership
What's next for LifeBio?
With the recent capital deployment, LifeBio is poised to accelerate its research and development initiatives, particularly in refining its AI algorithms for deeper therapeutic impact. The strategic focus will likely shift toward broader integration with healthcare systems and long-term care facilities, where the demand for evidence-based, non-pharmacological interventions for Alzheimer's is rapidly increasing. By scaling its infrastructure, LifeBio aims to solidify its market leadership, transforming how society approaches aging and cognitive health through technology-driven empathy and data-backed storytelling.
See full LifeBio company page
